CR20170285A - Compuestos de triazolopirimidina y usos de los mismos - Google Patents

Compuestos de triazolopirimidina y usos de los mismos

Info

Publication number
CR20170285A
CR20170285A CR20170285A CR20170285A CR20170285A CR 20170285 A CR20170285 A CR 20170285A CR 20170285 A CR20170285 A CR 20170285A CR 20170285 A CR20170285 A CR 20170285A CR 20170285 A CR20170285 A CR 20170285A
Authority
CR
Costa Rica
Prior art keywords
triazolopirimidine
compounds
same
prc2
disease
Prior art date
Application number
CR20170285A
Other languages
English (en)
Inventor
Man Zhang
Kehao Zhao
Wei; Qi
Long Wang
Ji Yue Zhang (Jeff);
Xiang-Ju Justin Gu
Hailong Zhang
Ho Man Chan
Ling; Li
Martin Sendzik
Qiong Zhang
Yongfeng Sun
Ying; Huang
Yuan Mi
Zhengtian Yu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR20170285A publication Critical patent/CR20170285A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Se proporciona un compuesto de la Fórmula (I), o una sal farmacéuticamente aceptable del mismo, el cual se ha mostrado es útil para tratar una enfermedad o trastorno mediado por PRC2 : en donde R1, R2, R3, R4, R5, y n son como se definen en la presente.
CR20170285A 2014-12-23 2015-12-21 Compuestos de triazolopirimidina y usos de los mismos CR20170285A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014094644 2014-12-23
CN2015095320 2015-11-23
PCT/IB2015/059843 WO2016103155A1 (en) 2014-12-23 2015-12-21 Triazolopyrimidine compounds and uses thereof

Publications (1)

Publication Number Publication Date
CR20170285A true CR20170285A (es) 2017-08-21

Family

ID=55071101

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170285A CR20170285A (es) 2014-12-23 2015-12-21 Compuestos de triazolopirimidina y usos de los mismos

Country Status (40)

Country Link
US (5) US10220036B2 (es)
EP (1) EP3237418B1 (es)
JP (1) JP6736559B2 (es)
KR (1) KR102534028B1 (es)
CN (1) CN107108637B (es)
AU (1) AU2015370524B2 (es)
BR (1) BR112017010354B8 (es)
CA (1) CA2969090C (es)
CL (1) CL2017001572A1 (es)
CO (1) CO2017005992A2 (es)
CR (1) CR20170285A (es)
CY (1) CY1121901T1 (es)
DK (1) DK3237418T3 (es)
DO (1) DOP2017000149A (es)
EA (1) EA032416B1 (es)
EC (1) ECSP17047153A (es)
ES (1) ES2722048T3 (es)
GT (1) GT201700146A (es)
HR (1) HRP20190805T1 (es)
HU (1) HUE043060T2 (es)
IL (1) IL252135B (es)
JO (1) JO3489B1 (es)
LT (1) LT3237418T (es)
ME (1) ME03385B (es)
MX (1) MX2017008529A (es)
MY (1) MY186837A (es)
NZ (1) NZ731664A (es)
PE (1) PE20171307A1 (es)
PH (1) PH12017501016B1 (es)
PL (1) PL3237418T3 (es)
PT (1) PT3237418T (es)
RS (1) RS58679B1 (es)
SG (1) SG11201703880VA (es)
SI (1) SI3237418T1 (es)
SV (1) SV2017005472A (es)
TN (1) TN2017000204A1 (es)
TW (1) TWI694076B (es)
UA (1) UA120945C2 (es)
UY (1) UY36462A (es)
WO (1) WO2016103155A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ731664A (en) * 2014-12-23 2024-02-23 Novartis Ag Triazolopyrimidine compounds and uses thereof
CA3025933A1 (en) 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
US11091489B2 (en) * 2016-06-20 2021-08-17 Novartis Ag Crystalline forms of a triazolopyrimidine compound
WO2017221100A1 (en) 2016-06-20 2017-12-28 Novartis Ag Imidazopyrimidine compounds useful for the treatment of cancer
CN109906224B (zh) * 2016-06-20 2022-02-25 诺华股份有限公司 三唑吡啶化合物及其应用
KR20230156174A (ko) 2016-07-12 2023-11-13 레볼루션 메디슨즈, 인크. 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
CN106831601A (zh) * 2017-01-13 2017-06-13 河北博伦特药业有限公司 一种2‑氨基甲基嘧啶盐酸盐及其衍生物的合成方法
CN110446709B (zh) 2017-01-23 2023-09-12 锐新医药公司 作为变构shp2抑制剂的二环化合物
AU2018210196B2 (en) 2017-01-23 2022-06-02 Revolution Medicines, Inc. Pyridine compounds as allosteric SHP2 inhibitors
WO2018170290A1 (en) * 2017-03-15 2018-09-20 Fulcrum Therapeutics, Inc. Compositions and methods for increasing fmr1 expression
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
CN109963854B (zh) * 2017-03-16 2022-04-12 江苏恒瑞医药股份有限公司 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用
US11602529B2 (en) 2017-06-02 2023-03-14 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
CN109575013A (zh) * 2017-09-28 2019-04-05 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
WO2019062435A1 (zh) * 2017-09-28 2019-04-04 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
RU2020115095A (ru) 2017-10-12 2021-11-12 Революшн Медсинз, Инк. Пиридиновые, пиразиновые и триазиновые соединения в качестве аллостерических ингибиторов shp2
CN109867645B (zh) * 2017-12-05 2021-09-14 中国医学科学院药物研究所 一种2,2-二氟-2,3-二氢取代苯并呋喃类化合物的合成方法
RU2020123241A (ru) 2017-12-15 2022-01-17 Революшн Медсинз, Инк. Полициклические соединения в качестве аллостерических ингибиторов shp2
CN109942556A (zh) * 2017-12-21 2019-06-28 上海青煜医药科技有限公司 嘧啶酮化合物及其应用
WO2019145176A1 (en) * 2018-01-23 2019-08-01 Basf Se Halogenation of pyridine derivatives
DK3746446T3 (da) 2018-01-31 2022-06-27 Mirati Therapeutics Inc PRC2-inhibitorer
CN110156787B (zh) * 2018-02-13 2021-11-02 中国科学院上海药物研究所 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途
CN110563722A (zh) * 2018-06-06 2019-12-13 上海青煜医药科技有限公司 吡啶或哒嗪并环化合物及其应用
CN110734436A (zh) * 2018-07-19 2020-01-31 上海青煜医药科技有限公司 嘧啶或吡嗪并环化合物及其应用
WO2020108590A1 (zh) * 2018-11-30 2020-06-04 上海拓界生物医药科技有限公司 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
CN111518100A (zh) * 2019-02-02 2020-08-11 上海青煜医药科技有限公司 环丙烯并苯并呋喃取代的氮杂芳基化合物及其应用
MX2021011118A (es) * 2019-03-15 2022-01-18 Fulcrum Therapeutics Inc Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2.
EP3950064A4 (en) * 2019-04-03 2023-01-04 Tera Stone Co., Ltd THYMINE NUCLEOBASE BASED TRIAZOLOPYRIMIDINES AND PROCESS FOR THEIR PRODUCTION
EP3959214A1 (en) * 2019-04-22 2022-03-02 Mirati Therapeutics, Inc. Naphthyridine derivatives as prc2 inhibitors
WO2020231723A1 (en) 2019-05-13 2020-11-19 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor
WO2020247706A1 (en) * 2019-06-05 2020-12-10 Athenex, Inc. Methods of treating and/or preventing psoriasis
CA3142711A1 (en) * 2019-06-05 2020-12-10 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer
AU2020332462B2 (en) * 2019-08-22 2023-08-17 Shanghai Blueray Biopharma Co., Ltd. Azaheteroaryl compound and application thereof
WO2021057853A1 (en) * 2019-09-26 2021-04-01 Novartis Ag Aza-quinoline compounds and uses thereof
AU2020374041B2 (en) * 2019-11-01 2024-02-08 Jing Medicine Technology (Shanghai) Ltd. EED inhibitor, and preparation method therefor and use thereof
CN113004233B (zh) * 2019-12-18 2022-12-20 南京优氟医药科技有限公司 一种用于制备prc2抑制剂的化合物、其制备方法和用途
CN111333655B (zh) * 2020-04-13 2021-07-13 武汉工程大学 一种三唑并嘧啶类化合物及其制备方法和应用
WO2021228034A1 (en) * 2020-05-11 2021-11-18 Ascentage Pharma (Suzhou) Co., Ltd. Preparation method of (5-fluoro-2, 3-dihydrobenzofuran-4-yl) methanamine or its salt, and intermediates thereof
CA3185154A1 (en) 2020-05-28 2021-12-02 Novartis Ag Dosing regimens for n-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine, or a pharmaceutically acceptable salt thereof, for use in treating prc2-mediated diseases or disorders
CN114907385A (zh) 2021-02-10 2022-08-16 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
WO2023016511A1 (zh) * 2021-08-11 2023-02-16 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
CN117384153A (zh) * 2022-07-12 2024-01-12 上海赛岚生物科技有限公司 一类甲基转移酶抑制剂及其用途

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
JP2002532415A (ja) 1998-12-16 2002-10-02 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤による関節炎の治療
NL1014106C2 (nl) 2000-01-18 2001-07-20 Univ Amsterdam Werkwijze voor het detecteren van een pathologische afwijking bij een cel, een antistof en een assay kit.
AU2001273498B2 (en) 2000-07-19 2006-08-24 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
SE519662C2 (sv) 2001-07-04 2003-03-25 Asept Int Ab Ventilanordning vid utportioneringsanordningar
US6894055B2 (en) * 2001-10-24 2005-05-17 Iconix Pharmaceuticals Inc. Thieno-2′,3′ -5,6pyrimido[3,4-A]-1,2,4-triazole derivatives as modulators of phoshoinositide 3-kinase
US6921762B2 (en) * 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
KR101210018B1 (ko) 2002-03-08 2012-12-07 에자이 알앤드디 매니지먼트 가부시키가이샤 약물로서 유용한 거대고리 화합물
SG148857A1 (en) 2002-03-13 2009-01-29 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
GB0228900D0 (en) 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
JP2004238296A (ja) 2003-02-04 2004-08-26 Kissei Pharmaceut Co Ltd 新規なトリアゾロピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
EP1639090A4 (en) 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING CANCER
US20060246505A1 (en) 2003-09-02 2006-11-02 Reinhard Walther Modulation of the synthesis of insulin
JP5160885B2 (ja) 2004-06-01 2013-03-13 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 再構成ヒストンメチルトランスフェラーゼ複合体及びそのモジュレーターの識別方法
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
AU2006272837B2 (en) 2005-07-21 2012-08-23 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of MEK
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US7890267B2 (en) 2006-03-31 2011-02-15 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
WO2008083251A2 (en) 2006-12-27 2008-07-10 Usc Stevens - University Of Southern California Dna methylation markers based on epigenetic stem cell signatures in cancer
WO2009017670A2 (en) 2007-07-26 2009-02-05 University Of Massachusetts Ras-mediated epigenetic silencing effectors and uses thereof
EP2426108B1 (en) 2007-08-29 2016-08-10 MethylGene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
MX338504B (es) 2007-09-12 2016-04-20 Genentech Inc Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
CA2701292C (en) 2007-10-25 2015-03-24 Genentech, Inc. Process for making thienopyrimidine compounds
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
GB0822248D0 (en) 2008-12-05 2009-01-14 Medical Res Council Crystal meths
WO2010111712A2 (en) 2009-03-27 2010-09-30 Cold Spring Harbor Laboratory Identification of rnai targets and use of rnai for rational therapy of chemotherapy-resistant leukemia and other cancers
CN102020643A (zh) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
BR112012028556A2 (pt) * 2010-05-07 2014-04-01 Glaxosmithkline Llc Indóis
RU2618475C2 (ru) 2010-09-10 2017-05-03 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
WO2012151277A1 (en) 2011-05-02 2012-11-08 Applied Informatic Solutions, Inc. Kits and methods for selecting a treatment for ovarian cancer
WO2013010181A2 (en) 2011-07-14 2013-01-17 University Of Massachusetts Methods of diagnosing cancer using epigenetic biomarkers
CA2850570A1 (en) 2011-09-30 2013-04-04 Glaxosmithkline Llc Methods of treating cancer
ES2718900T3 (es) 2012-03-12 2019-07-05 Epizyme Inc Inhibidores de EZH2 humana y métodos de uso de los mismos
CN105189506A (zh) 2012-11-19 2015-12-23 诺华股份有限公司 用于治疗寄生虫疾病的化合物和组合物
EP2934531A4 (en) 2012-12-19 2016-06-15 Glaxosmithkline Llc COMBINATION
WO2014124326A1 (en) 2013-02-08 2014-08-14 Stem Centrx, Inc. Novel multispecific constructs
CN105102446B (zh) 2013-02-11 2018-01-23 星座制药公司 甲基修饰酶的调节剂、其组合物及用途
CA2905070A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
US9776996B2 (en) * 2013-03-15 2017-10-03 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
HRP20220759T1 (hr) 2014-02-11 2022-09-02 Mitokinin, Inc. Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti
KR102486616B1 (ko) 2014-11-14 2023-01-09 바스프 에스이 질화작용 억제제로서의 벤질프로파르길에테르
PL3033944T3 (pl) 2014-12-16 2018-07-31 Omya International Ag Węglan wapnia do ochrony roślin
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
NZ731664A (en) * 2014-12-23 2024-02-23 Novartis Ag Triazolopyrimidine compounds and uses thereof
MA41272A (fr) 2014-12-23 2017-10-31 Adama Makhteshim Ltd 5-fluoro-4-imino-3-(alkyle/alkyle substitué)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one en tant que traitement des semences

Also Published As

Publication number Publication date
UY36462A (es) 2016-07-29
CL2017001572A1 (es) 2018-01-12
SV2017005472A (es) 2018-06-12
CA2969090C (en) 2023-05-02
PL3237418T3 (pl) 2019-07-31
HUE043060T2 (hu) 2019-07-29
DOP2017000149A (es) 2017-07-15
PH12017501016A1 (en) 2017-12-11
ECSP17047153A (es) 2019-02-28
EA032416B1 (ru) 2019-05-31
BR112017010354B1 (pt) 2022-09-20
LT3237418T (lt) 2019-05-10
AU2015370524A1 (en) 2017-06-01
EA201791420A1 (ru) 2017-10-31
TN2017000204A1 (en) 2018-10-19
WO2016103155A1 (en) 2016-06-30
MY186837A (en) 2021-08-25
UA120945C2 (uk) 2020-03-10
MX2017008529A (es) 2017-10-25
TW201629065A (zh) 2016-08-16
EP3237418A1 (en) 2017-11-01
IL252135B (en) 2020-06-30
CA2969090A1 (en) 2016-06-30
US9580437B2 (en) 2017-02-28
SG11201703880VA (en) 2017-07-28
IL252135A0 (en) 2017-07-31
ME03385B (me) 2020-01-20
CN107108637B (zh) 2019-10-29
SI3237418T1 (sl) 2019-06-28
CO2017005992A2 (es) 2017-10-20
PT3237418T (pt) 2019-05-23
GT201700146A (es) 2019-06-12
EP3237418B1 (en) 2019-01-30
NZ731664A (en) 2024-02-23
RS58679B1 (sr) 2019-06-28
PE20171307A1 (es) 2017-09-05
US10220036B2 (en) 2019-03-05
CY1121901T1 (el) 2020-10-14
US20200323859A1 (en) 2020-10-15
AU2015370524B2 (en) 2018-11-01
CN107108637A (zh) 2017-08-29
JO3489B1 (ar) 2020-07-05
US20160176882A1 (en) 2016-06-23
US20230033320A1 (en) 2023-02-02
DK3237418T3 (da) 2019-05-13
ES2722048T3 (es) 2019-08-07
US20170348312A1 (en) 2017-12-07
BR112017010354A2 (pt) 2017-12-26
JP2018500342A (ja) 2018-01-11
US11207325B2 (en) 2021-12-28
KR102534028B1 (ko) 2023-05-19
PH12017501016B1 (en) 2017-12-11
KR20170095882A (ko) 2017-08-23
HRP20190805T1 (hr) 2019-06-28
US11931363B2 (en) 2024-03-19
JP6736559B2 (ja) 2020-08-05
BR112017010354B8 (pt) 2022-10-18
TWI694076B (zh) 2020-05-21
US20190142837A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
DOP2017000149A (es) Compuestos de triazolopirimidina y usos de los mismos
CO2017001884A2 (es) Polimorfos de selinexor
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CU24605B1 (es) Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2
DOP2015000201A (es) Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
DOP2017000034A (es) Compuestos de imidazopiridazina
CU20160003A7 (es) Pirazololpiridinaminas sustituidas
AR095097A1 (es) Compuestos de fenoxietoxi
ECSP18003372A (es) Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
CL2019000487A1 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana.
AR098134A1 (es) Compuestos de urea
GT201500232A (es) Compuestos de azabencimidazol como inhibidores de las isozimas pde4 para el tratamiento de cns y otros trastornos
NZ767083A (en) Polymorphs of selinexor